NEW YORK, April 11, 2017 /PRNewswire/ --
Stock-Callers.com has initiated coverage on four Medical Laboratories andResearch equities, which are Biocept Inc. (NASDAQ: BIOC), Exact Sciences Corp. (NASDAQ: EXAS), and HTG Molecular Diagnostics Inc. (NASDAQ: HTGM). These companies operate in the Healthcare sector, which has received an "Outperform" rating from Charles
San Diego, California headquartered Biocept Inc.'s stock fell 4.12%, closing the day at $1.86, with a total trading volume of 455,558 shares. The Company's shares have advanced 82.35% in the previous three months and 140.00% since the start of this year. The stock is trading 61.50% above its 200-day moving average. Additionally, shares of Biocept, which develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample, have an RSI of 34.52.
On April 03rd, 2017, Biocept announced that it has entered into a Preferred Provider Collaboration and Services Agreement with Oregon Health & Sciences University on behalf of the OHSU Knight Cancer Institute (collectively, "OHSU"). The multiphase agreement grants OHSU the rights to commercially offer Biocept's Target Selector™ liquid biopsy testing services exclusively throughout the state of Oregon. The complimentary research report on BIOC can be accessed at:
On Monday, shares in Madison, Wisconsin headquartered Exact Sciences Corp. recorded a trading volume of 1.01 million shares. The stock ended the day 0.13% higher at $22.82. The Company's shares have advanced 6.79% in the past month, 26.92% in the previous three months, and 70.81% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 8.96% and 28.38%, respectively. Furthermore, shares of Exact Sciences, which focuses on developing products for the early detection and prevention of various cancers in the US, have an RSI of 60.23.
On April 04th, 2017, Exact Sciences announced that the Centers for Medicare and Medicaid Services included Cologuard® in its updated Medicare Advantage Star Ratings program. Medicare Advantage plans now can help increase their Star Ratings when their beneficiaries complete Cologuard, Exact Sciences' non-invasive colon cancer screening test. Register for free on Stock-Callers.com and download the PDF research report on EXAS at:
HTG Molecular Diagnostics
Tucson, Arizona-based HTG Molecular Diagnostics Inc.'s stock dropped 5.22%, finishing yesterday's session at $6.17, with a total trading volume of 2.08 million shares. The Company's shares have skyrocketed 171.09% in the last one month, 183.03% in the previous three months, and 175.45% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 90.04% and 141.84%, respectively. Additionally, shares of HTG Molecular Diagnostics, which develops and markets technology platforms that facilitate the routine use of complex molecular profiling, have an RSI of 56.44.
On March 23rd, 2017, HTG Molecular Diagnostics announced that the Company's HTG EdgeSeq technology has been successfully adapted for use with the QIAGEN GeneReader NGS System based on the results of initial technical feasibility tests. Get free access to your research report on HTGM at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Parotidectomy is a surgery to remove a part of or the entire parotid salivary gland, on the side of ...
Brugada syndrome is a rare genetic heart condition that affects the way electrical signals pass ...
Modified Atkins diet designed for weight loss and to treat seizures is high in fat and low in ...View All